Clinical trials
Phase 2 Hearing Loss trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2011 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 4 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sound Pharmaceuticals, Incorporated | 5 |
| US Department of Veterans Affairs | 5 |
| Autifony Therapeutics Limited | 2 |
| Northwestern University | 2 |
| AudioCure Pharma GmbH | 1 |
| Auris Medical AG | 1 |
| FDA Office of Orphan Products Development | 1 |
| GlaxoSmithKline | 1 |
| Kevin Winthrop | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hearing Loss | 30 |
| Tinnitus | 7 |
| Ototoxicity | 4 |
| Vertigo | 4 |
| Deafness | 3 |
| Ear Diseases | 2 |
| Head and Neck Neoplasms | 2 |
| Hearing Loss, Bilateral | 2 |
| Hearing Loss, Noise-Induced | 2 |
| Hearing Loss, Sensorineural | 2 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.